{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:35Z","timestamp":1793212115393,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen International GmbH"},{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40259-023-00616-3","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T08:01:35Z","timestamp":1693036895000},"page":"873-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune\u2010Mediated Inflammatory Disease"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct04089514","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Dignass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triana","family":"Lobaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Carron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier P.","family":"Gisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Utzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,26]]},"reference":[{"issue":"11","key":"616_CR1","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1172\/JCI36389","volume":"118","author":"FM Brennan","year":"2008","unstructured":"Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537\u201345. https:\/\/doi.org\/10.1172\/JCI36389.","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"616_CR2","doi-asserted-by":"publisher","first-page":"i77","DOI":"10.1136\/ard.2010.140582","volume":"70","author":"PJ Mease","year":"2011","unstructured":"Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(Suppl 1):i77. https:\/\/doi.org\/10.1136\/ard.2010.140582.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"616_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","volume":"12","author":"IB McInnes","year":"2016","unstructured":"McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis\u2014shaping the immunological landscape. Nat Rev Rheumatol. 2016;12(1):63\u20138. https:\/\/doi.org\/10.1038\/nrrheum.2015.171.","journal-title":"Nat Rev Rheumatol"},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3389\/fimmu.2018.02668","volume":"9","author":"A Watad","year":"2018","unstructured":"Watad A, Bridgewood C, Russell T, Marzo-Ortega H, Cuthbert R, McGonagle D. The early phases of ankylosing spondylitis: emerging insights from clinical and basic science. Front Immunol. 2018;9:2668. https:\/\/doi.org\/10.3389\/fimmu.2018.02668.","journal-title":"Front Immunol"},{"issue":"4","key":"616_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","volume":"50","author":"M Friedrich","year":"2019","unstructured":"Friedrich M, Pohin M, Powrie F. Cytokine networks in the pathophysiology of inflammatory bowel disease. Immunity. 2019;50(4):992\u20131006. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.017.","journal-title":"Immunity"},{"issue":"7","key":"616_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1056\/NEJMra1909094","volume":"385","author":"G Schett","year":"2021","unstructured":"Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628\u201339. https:\/\/doi.org\/10.1056\/NEJMra1909094.","journal-title":"N Engl J Med"},{"issue":"1","key":"616_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40744-020-00259-8","volume":"8","author":"TWJ Huizinga","year":"2021","unstructured":"Huizinga TWJ, Torii Y, Muniz R. Adalimumab biosimilars in the treatment of rheumatoid arthritis: a systematic review of the evidence for biosimilarity. Rheumatol Ther. 2021;8(1):41\u201361. https:\/\/doi.org\/10.1007\/s40744-020-00259-8.","journal-title":"Rheumatol Ther."},{"issue":"1_suppl","key":"616_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320140270S103","volume":"27","author":"G Lapadula","year":"2014","unstructured":"Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R, Chimenti S, et al. Adalimumab in the treatment of immune-mediated diseases. Int J Immunopathol Pharmacol. 2014;27(1_suppl):33\u201348. https:\/\/doi.org\/10.1177\/03946320140270S103.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"9","key":"616_CR9","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.1007\/s12325-020-01437-4","volume":"37","author":"MF Rezk","year":"2020","unstructured":"Rezk MF, Pieper B. Unlocking the value of anti-TNF biosimilars: reducing disease burden and improving outcomes in chronic immune-mediated inflammatory diseases: a narrative review. Adv Ther. 2020;37(9):3732\u201345. https:\/\/doi.org\/10.1007\/s12325-020-01437-4.","journal-title":"Adv Ther"},{"key":"616_CR10","doi-asserted-by":"publisher","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52:151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"13","key":"616_CR11","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1016\/j.cgh.2019.03.040","volume":"17","author":"J Burisch","year":"2019","unstructured":"Burisch J, Jess T, Egeberg A. Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark. Clin Gastroenterol Hepatol. 2019;17(13):2704-12.e3. https:\/\/doi.org\/10.1016\/j.cgh.2019.03.040.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"616_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/heartjnl-2019-316378","volume":"108","author":"R Agca","year":"2022","unstructured":"Agca R, Smulders Y, Nurmohamed M. Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice. Heart. 2022;108(1):73\u20139. https:\/\/doi.org\/10.1136\/heartjnl-2019-316378.","journal-title":"Heart"},{"issue":"11","key":"616_CR13","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","volume":"148","author":"JJ Wu","year":"2012","unstructured":"Wu JJ, Poon KYT, Channual JC, Shen AYJ. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244\u201350. https:\/\/doi.org\/10.1001\/archdermatol.2012.2502.","journal-title":"Arch Dermatol"},{"key":"616_CR14","unstructured":"AbbVie Inc. HUMIRA\u00ae FDA Prescribing Information. United States Food and Drug Administration. 2021. https:\/\/www.rxabbvie.com\/pdf\/humira.pdf. Accessed 14 Jan 2023."},{"key":"616_CR15","unstructured":"AbbVie Inc. HUMIRA\u00ae EMA Summary of Product Characteristics. European Medicines Agency. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Accessed 14 Jan 2023."},{"issue":"6","key":"616_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jcpt.12583","volume":"42","author":"D Shin","year":"2017","unstructured":"Shin D, Lee Y, Kim H, K\u00f6rnicke T, Fuhr R. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672\u20138. https:\/\/doi.org\/10.1111\/jcpt.12583.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"616_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/art.40336","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, et al. Phase III randomized study of SB5, an adalimumab biosimilar, versus reference adalimumab in patients with moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol. 2018;70(1):40\u20138. https:\/\/doi.org\/10.1002\/art.40336.","journal-title":"Arthritis Rheumatol"},{"key":"616_CR18","unstructured":"Biogen Inc. IMRALDI\u00ae EMA Summary of Product Characteristics. European Medicines Agency. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imraldi-epar-product-information_en.pdf. Accessed 14 Jan 2023."},{"issue":"4","key":"616_CR19","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"J Coghlan","year":"2021","unstructured":"Coghlan J, He H, Schwendeman AS. Overview of Humira\u00ae biosimilars: current European landscape and future implications. J Pharm Sci. 2021;110(4):1572\u201382. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.003.","journal-title":"J Pharm Sci"},{"issue":"6","key":"616_CR20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/art.40444","volume":"70","author":"ME Weinblatt","year":"2018","unstructured":"Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, et al. Switching from reference adalimumab to SB5 (adalimumab biosimilar) in patients with rheumatoid arthritis. Arthritis Rheumatol. 2018;70(6):832\u201340. https:\/\/doi.org\/10.1002\/art.40444.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"616_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/14712598.2022.2012146","volume":"22","author":"JP Gisbert","year":"2022","unstructured":"Gisbert JP, Gaffney K, Young D, Ebbers HC, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. Expert Opin Biol Ther. 2022;22(2):109\u201321. https:\/\/doi.org\/10.1080\/14712598.2022.2012146.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"616_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62\u201370. https:\/\/doi.org\/10.1056\/NEJMra1510062.","journal-title":"N Engl J Med"},{"issue":"20","key":"616_CR23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191\u20134. https:\/\/doi.org\/10.1001\/jama.2013.281053.","journal-title":"JAMA"},{"issue":"3","key":"616_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5152\/eurjrheum.2020.19199","volume":"7","author":"Leong KP, Tan JWL, Gao X, Koh ET, Group TRAS","year":"2020","unstructured":"Leong KP, Tan JWL, Gao X, Koh ET, Group TRAS. Conversion among the 28-joint count activity indices for rheumatoid arthritis. Eur J Rheumatol. 2020;7(3):105\u201311. https:\/\/doi.org\/10.5152\/eurjrheum.2020.19199.","journal-title":"Eur J Rheumatol"},{"key":"616_CR25","unstructured":"MedDRA Maintenance and Support Services Organization. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 23.0. McLean, Virginia [updated 2020 March]. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_23_0_English.pdf. Accessed 14 Jan 2023."},{"key":"616_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-77244-8","volume-title":"Clinical prediction models: a practical approach to development, validation, and updating","author":"EW Steyerberg","year":"2009","unstructured":"Steyerberg EW. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2009."},{"issue":"7","key":"616_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1080\/00365521.2022.2041082","volume":"57","author":"M Lukas","year":"2022","unstructured":"Lukas M, Kolar M, Reissigova J, Duricova D, Machkova N, Hruba V, et al. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn\u2019s disease: an analysis of two propensity score-matched cohorts. Scand J Gastroenterol. 2022;57(7):814\u201324. https:\/\/doi.org\/10.1080\/00365521.2022.2041082.","journal-title":"Scand J Gastroenterol"},{"key":"616_CR28","doi-asserted-by":"publisher","first-page":"1759720X2110336","DOI":"10.1177\/1759720X211033679","volume":"13","author":"C Bruni","year":"2021","unstructured":"Bruni C, Gentileschi S, Pacini G, Bardelli M, Tofani L, Bartoli F, et al. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211033679. https:\/\/doi.org\/10.1177\/1759720X211033679.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"12","key":"616_CR29","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/ecco-jcc\/jjab100","volume":"15","author":"LAAP Derikx","year":"2021","unstructured":"Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, et al. Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-na\u00efve SB5 observational cohorts. J Crohns Colitis. 2021;15(12):2011\u201321. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab100.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"616_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s40744-022-00465-6","volume":"9","author":"RCS van Adrichem","year":"2022","unstructured":"van Adrichem RCS, Voorneveld HJE, Waverijn GJ, Kok MR, Bisoendial RJ. The non-medical switch from reference adalimumab to biosimilar adalimumab is highly successful in a large cohort of patients with stable inflammatory rheumatic joint diseases: a real-life observational study. Rheumatol Ther. 2022;9(4):1109\u201318. https:\/\/doi.org\/10.1007\/s40744-022-00465-6.","journal-title":"Rheumatol Ther."},{"key":"616_CR31","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) for Imraldi. EMA\/CHMP\/106922\/2017. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/imraldi-epar-public-assessment-report_en.pdf. Accessed 13 Feb 2023."},{"issue":"1","key":"616_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-020-05199-w","volume":"40","author":"C Bruni","year":"2021","unstructured":"Bruni C, Bitti R, Nacci F, Cometi L, Tofani L, Bartoli F, et al. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases. Clin Rheumatol. 2021;40(1):85\u201391. https:\/\/doi.org\/10.1007\/s10067-020-05199-w.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"616_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.gastrohep.2019.06.008","volume":"43","author":"C Gely","year":"2020","unstructured":"Gely C, Mar\u00edn L, Gordillo J, Ma\u00f1osa M, Bertoletti F, Ca\u00f1ete F, et al. Impact of pain associated with the subcutaneous administration of adalimumab. Gastroenterol Hepatol (N Y). 2020;43(1):9\u201313. https:\/\/doi.org\/10.1016\/j.gastrohep.2019.06.008.","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"4","key":"616_CR34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/1756-185X.13803","volume":"23","author":"F Salaffi","year":"2020","unstructured":"Salaffi F, Di Carlo M, Farah S, Carotti M. Adherence to subcutaneous anti-TNF\u03b1 agents in patients with rheumatoid arthritis is largely influenced by pain and skin sensations at the injection site. Int J Rheum Dis. 2020;23(4):480\u20137. https:\/\/doi.org\/10.1111\/1756-185X.13803.","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"616_CR35","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"616_CR36","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2468-1253(21)00252-1","volume":"6","author":"S Hanauer","year":"2021","unstructured":"Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn\u2019s disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Lancet Gstroenterol Hepatol. 2021;6(10):816\u201325. https:\/\/doi.org\/10.1016\/S2468-1253(21)00252-1.","journal-title":"Lancet Gstroenterol Hepatol."},{"issue":"12","key":"616_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190147","volume":"12","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in Europe: an overview. PLoS ONE. 2017;12(12): e0190147. https:\/\/doi.org\/10.1371\/journal.pone.0190147.","journal-title":"PLoS ONE"},{"key":"616_CR38","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fphar.2019.01372","volume":"10","author":"L Colloca","year":"2019","unstructured":"Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10:1372. https:\/\/doi.org\/10.3389\/fphar.2019.01372.","journal-title":"Front Pharmacol"},{"issue":"Supplement_1","key":"616_CR39","doi-asserted-by":"publisher","first-page":"S406-S","DOI":"10.1093\/ecco-jcc\/jjab076.520","volume":"15","author":"T De Somer","year":"2021","unstructured":"De Somer T, Deprez N, Baert D, Deceuninck M, Huys I, Mattens V, et al. P396 Acceptance of switch, patient satisfaction and adverse events after switch from adalimumab originator to biosimilar SB5 in patients with Inflammatory Bowel Disease in a real-life setting. J Crohns Colitis. 2021;15(Supplement_1):S406-S. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab076.520.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"616_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect. 2016;4(2): e00208. https:\/\/doi.org\/10.1002\/prp2.208.","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"616_CR41","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41584-018-0110-9","volume":"14","author":"E Kravvariti","year":"2018","unstructured":"Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol. 2018;14(12):727\u201340. https:\/\/doi.org\/10.1038\/s41584-018-0110-9.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"616_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1185\/03007995.2010.534959","volume":"27","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Hobar C, Hansbrough K. Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. Curr Med Res Opin. 2011;27(1):71\u20138. https:\/\/doi.org\/10.1185\/03007995.2010.534959.","journal-title":"Curr Med Res Opin"},{"issue":"Supplement 1","key":"616_CR43","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1093\/ecco-jcc\/jjab076.706","volume":"15","author":"D Young","year":"2021","unstructured":"Young D, Latter S, Harvey J, Addison J, Freudensprung U, Cummings F. P585 IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective. J Crohns Colitis. 2021;15(Supplement 1):S537\u20138. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab076.706.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"616_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050949","volume":"12","author":"K Kaneko","year":"2022","unstructured":"Kaneko K, Prieto-Alhambra D, Jacklin C, Bosworth A, Dickinson S, Berry S, et al. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients\u2019 satisfaction: a cross-sectional survey by patient organisations. BMJ Open. 2022;12(2): e050949. https:\/\/doi.org\/10.1136\/bmjopen-2021-050949.","journal-title":"BMJ Open"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00616-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00616-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:36:15Z","timestamp":1697542575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00616-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,26]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00616-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,26]]},"assertion":[{"value":"7 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. This study was funded by Biogen International GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ulf M\u00fcller-Ladner has served as a speaker\/advisor for Biogen, AbbVie, and Medac. Axel Dignass has received fees for participation in clinical trials and for review activities, such as data monitoring boards, statistical analysis, and endpoint committees from Abivax, AbbVie, Arena, Celgene\/Bristol Myers Squibb, Falk, Gilead, Janssen, and Pfizer; consultancy fees from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene\/Bristol Myers Squibb, Celltrion, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, Eli Lilly, MSD, Pfizer, Pharmacosmos, Roche\/Genentech, Sandoz\/Hexal, Takeda, Tillotts, and Vifor; and payment for lectures including service on speaker bureaus from AbbVie, Amgen, Biogen, Celltrion, Falk Foundation, Ferring, Gilead\/Galapagos, Janssen, Eli Lilly, MSD, Pharmacosmos, Pfizer, Takeda, Tillotts, and Vifor. Karl Gaffney has received research grants from NASS, AbbVie, UCB, Novartis, Eli Lilly, Celgene, Celltrion, Janssen, Gilead, and Biogen; consultancy fees\/honoraria from AbbVie, Eli Lilly, and Novartis; and speaker\/bureau fees from AbbVie, UCB, Novartis, and Eli Lilly. Deepak Jadon has received research grants, education grants, and\/or consulting fees or honoraria from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Fresenius Kabi, Galapagos\/Gilead, GSK, Healthcare Celltrion, Janssen, Merck, Novartis, Pfizer, Roche, and Sandoz. Marco Matucci-Cerinic has received research grants from MSD and speaker fees from Sandoz, Boehringer\u00a0Ingelheim, and Biogen. Triana Lobaton has received financial research support from AbbVie, Viatris, MSD, Mundipharma, Biogen, Janssen, Pfizer, and Takeda; speaker fees from Ferring, MSD, AbbVie, Janssen, Amgen, Fresenius Kabi, Galapagos, Viatris, and Takeda; and consultancy fees from Janssen, Galapagos, Amgen, Bristol Myers Squibb, Fresenius Kabi, and Takeda. Philippe Carron has received consulting\/speaker\u2019s fees from AbbVie, Biogen, Eli Lilly, Fresenius Kabi, Galapagos, MSD, Pfizer, and UCB. Javier P. Gisbert has served as a speaker, consultant, and advisory member for, or has received research funding from, MSD, AbbVie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, Janssen, Roche, Sandoz, Celgene\/Bristol Myers\u00a0Squibb, Gilead\/Galapagos, Eli Lilly, Ferring, Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine, and Vifor Pharma. Ira Pande has received research funding, consulting, speaker fees, and sponsorship from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, MSD, Pfizer, Proctor & Gamble, and Roche. Maximilian Utzinger and Janet Addison are employees of Biogen and may hold company stock.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data pertaining to this research will not be shared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The protocol, its amendment, and the patient-informed consent form were approved by the Ethics Committees of the participating sites. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and all applicable local regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Prior to enrolling a patient into the study or entering any patient data into the electronic Case Report Form, the Investigator was responsible for obtaining written informed consent from the patient through an Ethics-Committee-approved Informed Consent Form (ICF) in accordance with local practice and regulations. The patient was asked to sign the ICF only after receiving an explanation of the backgrounds, methods, procedures, and benefits and potential risks of the study, and being informed that their participation was voluntary.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JA developed the concept for this publication, developed the methodology, and acquired funding. Formal analysis and investigation were conducted by JA and MU who, along with UM-L, prepared the original draft of the manuscript. All authors were involved in the review and editing of the draft manuscript. KG, DJ, MM-C, TL, PC, and IP were principal investigators at their respective study sites. Supervision for this study was provided by JA, MU, UM-L, AD, DJ, TL, PC, JG, and MM-C. All authors read and approved the final version of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}